Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Prevents organ rejection. Sold as Cellcept. Every FDA application for this active ingredient: 1 branded and 9 generic.
As of Nov 15, 2026, FDA lists 10 applications for Mycophenolate Mofetil Hydrochloride (sold as Cellcept), first approved Aug 12, 1998, with 3 new uses approved and 0 published complete response letters.
First approved: Aug 12, 1998
Applications: 10
New uses approved: 3
Complete response letters: 0
Medicare spending, 2025: $0K
First approved in the EU: Feb 14, 1996
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Product
Part
Spending, 2025
Change
Beneficiaries
CELlcept (J7519)
Part B
$0K
-100%
0
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
CELLCEPT 200 MG/ML ORAL SUSP: $8.31 per MLBrand · 0% in a year
CELLCEPT 250 MG CAPSULE: $8.64 per unitBrand · 0% in a year
CELLCEPT 500 MG TABLET: $17.36 per unitBrand · +0% in a year
CellceptDrugs with a new indication and a new dosage for the treatment of refractory nephrotic syndrome (for use frequent relapsing or steroid-dependent nephrotic… · [1] [2] Chugai Pharmaceutical Co., Ltd., [3] Viatris Healthcare G.K. · Sep 19, 2025
CellceptDrugs with a new indication and a new dosage for the treatment of systemic sclerosis-associated interstitial lung disease. · Chugai Pharmaceutical Co., Ltd. · Jun 24, 2024
CellceptDrugs with a new indication and a new dosage for the suppression of graft-versus-host disease in hematopoietic stem cell transplantation. · (1) (2) Chugai Pharmaceutical Co., Ltd. (3) Mylan Seiyaku Ltd. · Jun 25, 2021
CellceptDrugs with a new additional indication and a new dosage for the treatment of lupus nephritis. · Mylan Seiyaku Ltd. · May 13, 2016
CellceptA drug with a new additional pediatric dosage indicated for the prevention of rejection in renal transplantation. · Chugai Pharmaceutical Co., Ltd. · Sep 16, 2011
Clinical Trials
6 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Mylan Labs Ltd
Zydus Pharms